327 related articles for article (PubMed ID: 33516338)
21. Public health impact and return on investment of Belgium's pediatric immunization program.
Carrico J; Mellott CE; Talbird SE; Bento-Abreu A; Merckx B; Vandenhaute J; Benchabane D; Dauby N; Ethgen O; Lepage P; Luyten J; Raes M; Simoens S; Van Ranst M; Eiden A; Nyaku MK; Bencina G
Front Public Health; 2023; 11():1032385. PubMed ID: 37427250
[TBL] [Abstract][Full Text] [Related]
22. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria.
Anderson JD; Pecenka CJ; Bagamian KH; Rheingans RD
PLoS One; 2020; 15(5):e0232941. PubMed ID: 32469927
[TBL] [Abstract][Full Text] [Related]
23. Effect of vaccination programmes on mortality burden among children and young adults in the Netherlands during the 20th century: a historical analysis.
van Wijhe M; McDonald SA; de Melker HE; Postma MJ; Wallinga J
Lancet Infect Dis; 2016 May; 16(5):592-598. PubMed ID: 26873665
[TBL] [Abstract][Full Text] [Related]
24. COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
Pearson CAB; Bozzani F; Procter SR; Davies NG; Huda M; Jensen HT; Keogh-Brown M; Khalid M; Sweeney S; Torres-Rueda S; ; ; Eggo RM; Vassall A; Jit M
PLoS Med; 2021 Oct; 18(10):e1003815. PubMed ID: 34606520
[TBL] [Abstract][Full Text] [Related]
25. The impact of Measles-Rubella vaccination on the morbidity and mortality from Congenital Rubella Syndrome in 92 countries.
Vynnycky E; Papadopoulos T; Angelis K
Hum Vaccin Immunother; 2019; 15(2):309-316. PubMed ID: 30285537
[TBL] [Abstract][Full Text] [Related]
26. Equity impact of HPV vaccination on lifetime projections of cervical cancer burden among cohorts in 84 countries by global, regional, and income levels, 2010-22: a modelling study.
Abbas K; Yoo KJ; Prem K; Jit M
EClinicalMedicine; 2024 Apr; 70():102524. PubMed ID: 38685933
[TBL] [Abstract][Full Text] [Related]
27. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
[TBL] [Abstract][Full Text] [Related]
28. Pneumococcal conjugate vaccination in The Gambia: health impact, cost effectiveness and budget implications.
Pecenka C; Usuf E; Hossain I; Sambou S; Vodicka E; Atherly D; Mackenzie G
BMJ Glob Health; 2021 Dec; 6(12):. PubMed ID: 34916274
[TBL] [Abstract][Full Text] [Related]
29. Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness.
Rheingans R; Atherly D; Anderson J
Vaccine; 2012 Apr; 30 Suppl 1():A15-23. PubMed ID: 22520124
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.
Patel HD; Roberts ET; Constenla DO
Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497
[TBL] [Abstract][Full Text] [Related]
31. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010.
Feigin VL; Forouzanfar MH; Krishnamurthi R; Mensah GA; Connor M; Bennett DA; Moran AE; Sacco RL; Anderson L; Truelsen T; O'Donnell M; Venketasubramanian N; Barker-Collo S; Lawes CM; Wang W; Shinohara Y; Witt E; Ezzati M; Naghavi M; Murray C;
Lancet; 2014 Jan; 383(9913):245-54. PubMed ID: 24449944
[TBL] [Abstract][Full Text] [Related]
32. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden.
Kim SY; Sweet S; Chang J; Goldie SJ
BMC Infect Dis; 2011 Jun; 11():174. PubMed ID: 21679420
[TBL] [Abstract][Full Text] [Related]
33. Status of New Vaccine Introduction - Worldwide, September 2016.
Loharikar A; Dumolard L; Chu S; Hyde T; Goodman T; Mantel C
MMWR Morb Mortal Wkly Rep; 2016 Oct; 65(41):1136-1140. PubMed ID: 27764083
[TBL] [Abstract][Full Text] [Related]
34. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
35. Use of controlled temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs: a modelling and cost-optimisation study.
Seaman CP; Morgan C; Howell J; Xiao Y; Spearman CW; Sonderup M; Lesi O; Andersson MI; Hellard ME; Scott N
Lancet Glob Health; 2020 Jul; 8(7):e931-e941. PubMed ID: 32562649
[TBL] [Abstract][Full Text] [Related]
36. Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches.
Watts E; Sim SY; Constenla D; Sriudomporn S; Brenzel L; Patenaude B
Value Health; 2021 Jan; 24(1):78-85. PubMed ID: 33431157
[TBL] [Abstract][Full Text] [Related]
37. Estimating total spending by source of funding on routine and supplementary immunisation activities in low-income and middle-income countries, 2000-17: a financial modelling study.
Ikilezi G; Micah AE; Bachmeier SD; Cogswell IE; Maddison ER; Stutzman HN; Tsakalos G; Brenzel L; Dieleman JL
Lancet; 2021 Nov; 398(10314):1875-1893. PubMed ID: 34742369
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
[TBL] [Abstract][Full Text] [Related]
39. Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis.
Paternina-Caicedo A; De la Hoz-Restrepo F; Alvis-Guzmán N
Pediatr Infect Dis J; 2015 Jul; 34(7):e176-84. PubMed ID: 25923424
[TBL] [Abstract][Full Text] [Related]
40. National, State, and Selected Local Area Vaccination Coverage Among Children Aged 19-35 Months - United States, 2014.
Hill HA; Elam-Evans LD; Yankey D; Singleton JA; Kolasa M
MMWR Morb Mortal Wkly Rep; 2015 Aug; 64(33):889-96. PubMed ID: 26313470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
